Status Asthmaticus

Definition

• PEFR or FEV1 does not improve to >40% predicted with treatment
• Rising PaCO2 without improvement in airflow obstruction (ominous sign - asthmatics normally hyperventilate and have low PaCO2)
• Development of a major complication: pneumothorax, pneumomediastinum, acute myocardial ischemia, or cardiac tachyarrhythmia (other than sinus tachycardia)

Pathophysiology

• Bronchial smooth muscle contraction + mucosal edema + thick secretions narrow airways
• Mucous plugging: airways fill with inspissated mucus (seen at autopsy in fatal cases)
• Mediators released: histamine, leukotrienes, tryptase, prostaglandins from mast cells (IgE-dependent)
• Gas trapping leads to auto-PEEP, dynamic hyperinflation, increased work of breathing
• Ventilation-perfusion mismatch produces hypoxemia; early hyperventilation (low PaCO2) progresses to rising PaCO2 as the patient tires - a pre-arrest sign

Clinical Features

Treatment

First-Line: Short-Acting Beta-2 Agonists (SABA)

• Mild-moderate: 2.5-5 mg by nebulizer (0.15 mg/kg in children, min 2.5 mg, max 5 mg) every 20 min for 3 doses, then every 1-4 hours
• Severe: Continuous nebulization at 0.5 mg/kg/hr (max 30 mg/hr in children)
• MDI with spacer is preferred when the patient can cooperate - equal or greater efficacy, fewer side effects

Anticholinergics

• Nebulizer: 0.25-0.5 mg every 20 min for 3 doses in the ED
• Note: No additional benefit shown in the inpatient setting; benefit is primarily in the ED phase

Systemic Corticosteroids

Oxygen

IV Magnesium Sulfate

• Indicated for very severe asthma (FEV1/PEFR <25% predicted) when not responding to initial therapy
• Adult dose: 1-2 g IV over 20-30 minutes
• Pediatric dose: 25-75 mg/kg IV (max 2 g) over 20 min
• Mechanism: smooth muscle relaxation via calcium channel blockade
• Monitor BP and deep tendon reflexes; hypotension is rare but possible

Adjunct Therapies

Ketamine

• Bronchodilatory properties via catecholamine release and NMDA receptor blockade
• Dose: 0.15 mg/kg IV bolus then 0.25 mg/kg/hr infusion (sub-dissociative)
• Pediatric: 1-2 mg/kg IV load then 1 mg/kg/hr infusion
• Excellent induction agent for RSI in status asthmaticus (ketamine 1.5 mg/kg IV is the agent of choice)

Heliox (80% He / 20% O2)

• Lowers airway resistance via reduced gas density
• No role in routine care, but an option for patients refractory to standard therapy
• Limits inspired FiO2 - do not use if patient is severely hypoxic

Epinephrine (Subcutaneous/IM)

• 0.5 mg SC or IM in adults for refractory bronchospasm
• Pediatric: 0.01 mg/kg of 1 mg/mL IM (max 0.5 mg) every 15-20 min for up to 3 doses
• Terbutaline SC: 0.01 mg/kg (max 0.25 mg) every 20 min for up to 3 doses

Terbutaline IV (Pediatric)

• IV load: 4-10 mcg/kg, then 0.2-5 mcg/kg/min continuous infusion
• Consider for severe exacerbation with minimal air entry; may decrease need for mechanical ventilation

Aminophylline

• No longer first- or second-line for acute asthma
• Can be used as adjunct in hospitalized status asthmaticus patients: 5-6 mg/kg IV load over 20-30 min, then 30-60 mg/hr infusion (target level 15-20 mcg/mL)
• Risk of toxicity (tachycardia, seizures at levels >30 mcg/mL) limits use
• Pediatric: 6 mg/kg IV load, then 0.5-1.2 mg/kg/hr (age-dependent)

Noninvasive Positive-Pressure Ventilation (NIPPV/BiPAP)

• Reduces work of breathing and may decrease need for intubation
• Well tolerated by children with status asthmaticus
• Contraindicated if: altered sensorium, near-collapse, or pneumothorax
• Also useful as pre-oxygenation before RSI

Intubation: RSI Protocol

Post-Intubation Mechanical Ventilation Strategy

• Permissive hypoventilation (controlled hypoventilation): tolerate hypercapnia to minimize auto-PEEP and barotrauma
• Respiratory rate: 12-14 breaths/min (low to allow full exhalation)
• High inspiratory flow rate (allows longer expiratory time)
• Tidal volume: 6-8 mL/kg (lung-protective)
• Target SpO2 ≥90% - do not chase normal PaCO2
• Monitor for auto-PEEP, barotrauma, hemodynamic compromise (decreased preload from air trapping)
• Avoid prolonged neuromuscular blockade - risk of post-extubation myopathy
• Sedation is mandatory during mechanical ventilation

Agents of No Proven Benefit

• IV antibiotics: not indicated unless clear bacterial infection
• Anxiolytics (without airway protection): can suppress respiratory drive
• Lidocaine IV before intubation: no high-level evidence supporting it
• Aminophylline (methylxanthines): removed from first/second-line algorithms; only adjunct role

Extracorporeal Life Support (ECLS)

Pediatric-Specific Considerations

• Viral respiratory infections account for 80% of acute asthma triggers in children
• Dexamethasone preferred over prednisolone in children (palatability, fewer doses)
• Continuous albuterol nebulization in severe cases
• Terbutaline IV can be a bridge to avoid mechanical ventilation
• A 2025 network meta-analysis in Pediatric Pulmonology examined IV bronchodilators in pediatric critical asthma and may further refine the optimal IV bronchodilator choice in children (PMID: 40637351)

A 2024 systematic review (Crit Care, 2024) on sevoflurane for refractory status asthmaticus in adults supports its use as a rescue bronchodilator when standard therapy fails - this is an emerging option available in ICU/theatre settings (PMID: 39402635).